Thalidomide has a significant effect in patients with thalassemia intermedia

References

• Origa R. β-Thalassemia. Genet Med. 2016. DOI:10.1038/gim.2016.173
   PubMed Web of Science ®Google Scholar
• Padate B, Bain BJ, de la Fuente J. Ineffective hemopoietic in beta thalassemia major visualised. Am J Hematol. 2011;86(4):372. doi: 10.1002/ajh.21953
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892. doi: 10.1182/blood-2009-09-243154
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Curr Med Res Opin. 2016;32(1):191–204. doi: 10.1185/03007995.2015.1110128
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). Nicosia: Thalassaemia International Federation;2013.
   Google Scholar
• Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995;80(1):58–68.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang X, Shang X, et al. The molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity. BMC Med Genet. 2010;13:31.
   Web of Science ®Google Scholar
• Xiong F, Sun M, Zhang X, et al. Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China. Clin Genet. 2010;78(2):139–148. doi: 10.1111/j.1399-0004.2010.01430.x
   PubMed Web of Science ®Google Scholar
• Yin XL, Wu ZK, He YY, et al. Treatment and complications of thalassemia major in Guangxi, Southern China. Pediatr Blood Cancer. 2011;57(7):1174–1178. doi: 10.1002/pbc.23101
   PubMed Web of Science ®Google Scholar
• Xu LH, Fang JP. The current status of β-thalassemia major in Mainland China. Hemoglobin. 2013;37(4):307–314. doi: 10.3109/03630269.2013.789967
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, El-Ghamrawy M, EL-Ela MA, et al. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years’ follow-up in Egypt. Ann Hematol. 2014;93(12):2045–2050. doi: 10.1007/s00277-014-2154-5
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Zafari M, Alipur A, et al. The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012. Hemoglobin. 2014;38(4):262–271. doi: 10.3109/03630269.2014.927770
   PubMed Web of Science ®Google Scholar
• Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, et al. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol Dis. 2008;41(1):136–137. doi: 10.1016/j.bcmd.2008.03.001
   PubMed Web of Science ®Google Scholar
• Fozza C, Pardini S, Giannico DB, et al. Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis. Am J Hematol. 2015;90(7):E141–E141. doi: 10.1002/ajh.24030
   PubMed Web of Science ®Google Scholar
• Ricchi P, Costantini S, Spasiano A, et al. The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with non-transfusion-dependent thalassemia. Blood Cells Mol Dis. 2016;57:97–99. doi: 10.1016/j.bcmd.2016.01.003
   PubMed Web of Science ®Google Scholar
• Masera N, Tavecchia L, Capra M, et al. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus. 2010;8(1):63–65.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD, et al. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523. doi: 10.1111/j.1365-2141.2010.08486.x
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Saunthararajah Y, Thayalasuthan V, et al. A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood. 2011;118(10):2708–2711. doi: 10.1182/blood-2011-03-341909
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Farhadi A, et al. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–56. doi: 10.1007/s12185-011-0985-6
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Adly AA, Ismail EA, et al. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. Eur J Haematol. 2013;91(6):522–533. doi: 10.1111/ejh.12182
   PubMed Web of Science ®Google Scholar
• Ch A, Alimirzoyeva Z, Hasanova M, et al. Clinical application of recombinant erythropoietin in beta-thalassaemia intermedia. Georgian Med News. 2016;255(6):86–92.
   Google Scholar
• Karimi M, Zarei T, Haghpanah S, et al. Relationship between some single-nucleotide polymorphism and response to hydroxyurea therapy in Iranian patients with ß-thalassemia intermedia. J Pediatr Hematol Oncol. 2017;39(4):e171–e176. doi: 10.1097/MPH.0000000000000779
   PubMed Web of Science ®Google Scholar
• Ehsani MA, Hedayati-Asl AA, Bagheri A, et al. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol. 2009;26(8):560–565. doi: 10.3109/08880010903271671
   PubMed Web of Science ®Google Scholar
• Fard AD, Kaviani S, Noruzinia M, et al. Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. Lab Hematol. 2013;19(1):1–5. doi: 10.1532/LH96.12003
   PubMedGoogle Scholar
• Aerbajinai W, Zhu J, Gao Z, et al. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood. 2007;110(8):2864–2871. doi: 10.1182/blood-2007-01-065201
   PubMed Web of Science ®Google Scholar
• Jalali FMA, Dehghani FA, Hajizamani S, et al. Thalidomide is more efficient than sodium butyrate in enhancing GATA-1 and EKLF gene expression in erythroid progenitors derived from HSCs with β-globin gene mutation. Int J Hematol Oncol Stem Cell Res. 2016;10(1):37–41.
   PubMedGoogle Scholar
• Italia KY, Jijina FF, Jain D, et al. The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies. Clin Biochem. 2010;43(16–17):1329–1332. doi: 10.1016/j.clinbiochem.2010.08.006
   PubMed Web of Science ®Google Scholar